Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3

被引：0
|
作者：
Papp, K. [1 ]
Leonardi, C. [2 ]
Blauvelt, A. [3 ]
Korman, N. [4 ]
Ohtsuki, M. [5 ]
Reich, K. [6 ,7 ]
Mallbris, L. [8 ]
Ball, S. [8 ]
Erickson, J. [8 ]
Griffiths, C. E. [9 ]
机构：
[1] Papp Clin Res & Prob Med Res, Waterloo, ON, Canada
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[5] Jichi Med Univ, Shimotsuke, Tochigi, Japan
[6] Dermatol Hamburg, Hamburg, Germany
[7] Georg August Univ, Hamburg, Germany
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Univ Manchester, Manchester, Lancs, England
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
058
引用
收藏
页码：S170 / S170
页数：1
相关论文
共 50 条
  • [1] Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)
    Papp, K. A.
    Leonardi, C. L.
    Blauvelt, A.
    Reich, K.
    Korman, N. J.
    Ohtsuki, M.
    Paul, C.
    Ball, S.
    Cameron, G. S.
    Erickson, J.
    Zhang, L.
    Mallbris, L.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (03) : 674 - 681
  • [2] Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
    Reich, Kristian
    Leonardi, Craig
    Lebwohl, Mark
    Kerdel, Francisco
    Okubo, Yukari
    Romiti, Ricardo
    Goldblum, Orin
    Dennehy, Ellen B.
    Kerr, Lisa
    Sofen, Howard
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (04) : 282 - 287
  • [3] Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
    Egeberg, Alexander
    Wu, Jashin J.
    Korman, Neil
    Solomon, James A.
    Goldblum, Orin
    Zhao, Fangyi
    Mallbris, Lotus
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (01) : 104 - +
  • [4] Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
    Menter, A.
    Warren, R. B.
    Langley, R. G.
    Merola, J. F.
    Kerr, L. N.
    Dennehy, E. B.
    Shrom, D.
    Amato, D.
    Okubo, Y.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1686 - 1692
  • [5] Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: A pooled analysis of data from two phase 3 randomized clinical trials (UNCOVER-2 and UNCOVER-3)
    Leonardi, C. L.
    Langley, R.
    Blauvelt, A.
    Gordon, K.
    Shrom, D. S.
    Farmer-Kerr, L. N.
    Stoykov, I.
    Ojeh, C.
    Reich, K.
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (03) : E29 - E30
  • [6] Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: A pooled analysis of data from two phase 3 randomized clinical trials (UNCOVER-2 and UNCOVER-3)
    Leonardi, Craig
    Langley, Richard
    Blauvelt, Andrew
    Gordon, Kenneth
    Shrom, David
    Kerr, Lisa
    Stoyko, Ivaylo
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB70 - AB70
  • [7] Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
    Kemeny, Lajos
    Berggren, Lovisa
    Dossenbach, Martin
    Dutronc, Yves
    Paul, Carle
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (01) : 19 - 26
  • [8] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    Griffiths, Christopher E. M.
    Reich, Kristian
    Lebwohl, Mark
    van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Cameron, Gregory S.
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta J.
    Ball, Susan
    Braun, Daniel K.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian J.
    Papp, Kim
    LANCET, 2015, 386 (9993): : 541 - 551
  • [9] Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3
    Leonardi, C. L.
    Blauvelt, A.
    Sofen, H. L.
    Gooderham, M.
    Augustin, M.
    Burge, R.
    Zhu, B.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (09) : 1483 - 1490
  • [10] Number needed to treat associated with ixekizumab and etanercept from UNCOVER-2 and UNCOVER-3 Phase III trials in the treatment of moderate-to-severe psoriasis
    Foster, S.
    Zhu, B.
    Burge, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S27 - S27
12345